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Through whole-mount in situ hybridisation screen on medaka (Oryzias latipes) brain, Ol-insm1b, a member of the Insm1/Mlt1 subfamily of
SNAG-domain containing genes, has been isolated. It is strongly expressed during neurogenesis and pancreas organogenesis, with a pattern that
suggests a role in cell cycle exit. Here, we describe Ol-insm1b expression pattern throughout development and in adult brain, and we report on its
functional characterisation. Our data point to a previously unravelled role for Ol-insm1b as a down-regulator of cell proliferation during
development, as it slows down the cycle without triggering apoptosis. Clonal analysis demonstrates that this effect is cell-autonomous, and,
through molecular dissection studies, we demonstrate that it is likely to be non-transcriptional, albeit mediated by zinc-finger domains.
Additionally, we report that Ol-insm1b mRNA, when injected in one cell of two-cell stage embryos, exhibits a surprising behaviour: it does not
spread uniformly amongst daughter cells but remains cytoplasmically localised in the progeny of the injected blastomere. Our experiments suggest
that Insm1 is a negative regulator of cell proliferation, possibly through mechanisms that do not involve modulation of transcription.
© 2007 Elsevier Inc. All rights reserved.Keywords: Insulinoma-Associated-1; Proliferation; Cell cycle arrest; Mid-blastula transition; Zinc-finger; Transcription factors; Medaka; FishIntroduction
Cell proliferation and differentiation are essential events in
organogenesis. The number of times progenitor cells divide
before they exit cell cycle and differentiate largely determines
the size of tissues and organs (Caviness et al., 2000; Hardcastle
and Papalopulu, 2000; Calle-Mustienes et al., 2002; Kango-
Sinh et al., 2002). Defects in cell cycle exit result in lack of cells
(if premature) or excess cells, and often underlie tumour prog-
ression (Tateno et al., 2001). It is therefore of great fundamental
and practical interest to characterise new negative regulators of
the cell cycle, which represent potential tumor suppressors. The
aim of the present paper is to characterise one such gene.
Our model is the medakaOryzias latipes, a teleost that shares
many of the zebrafish characteristics (Wittbrodt et al., 2002). We⁎ Corresponding author. Department of Cell Biology and Ecology, Faculty of
Biology, University of Santiago de Compostela, 15782-Santiago de Compos-
tela, Spain. Fax: +34 981 596 904.
E-mail address: ecandal@usc.es (E. Candal).
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doi:10.1016/j.ydbio.2007.04.038have used the medaka optic tectum (OT) as a system to identify
new cell cycle regulators (Nguyên et al., 2001a; Candal et al.,
2005a; Deyts et al., 2005). The medaka OT is a brain cortical
structure that grows continuously by addition of columns of cells
produced in a proliferative zone restricted to a crescent at its
medial, caudal and lateral margin (Nguyên et al., 1999).
Through whole-mount in situ hybridisation (WMISH)
screens (Nguyên et al., 2001a,b; Deyts et al., 2005), we un-
ravelled a wealth of molecules related to cell proliferation
(expression in the marginal proliferative zone; mpz), cell
differentiation (expression in the central differentiated zone)
and cell cycle arrest (expression in a zone at the border between
the two formers). We have thus previously characterised two
genes known to be involved in cell cycle arrest, which were
strongly expressed in the arrest zone. (1) Ol-KIP (O. latipes-
Kinase Inhibitor Protein; Nguyên et al., 2001b), an orthologue of
the cyclin-dependent kinase inhibitor p57KIP2 (Dyer and Cepko,
2000; Carey et al., 2002). (2) Ol-Gadd45γ, the O. latipes
orthologue of the mammalian Gadd45γ (a member of the
Gadd45 family of growth-arrest and DNA-damage inducible
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cells before both G1/S and G2/M cell cycle checkpoints.
We also found two potential, albeit poorly characterised,
negative growth regulators, i.e., genes with a strong expression
in the arrest zone of the medaka OT. These two genes (Ol-
insm1a and Ol-insm1b: O. latipes-insm1a and 1b) encode 440
and 498 amino acid proteins, respectively, and represent me-
daka co-orthologues of the mammalian gene Insm1 (formerly
Insulinoma-Associated-1; IA-1; Lan et al., 1994), a member
of the SNAG transcriptional repressor family.
This family (Grimes et al., 1996) is subdivided into three
subfamilies (present results and Tateno et al., 2001): (a) Snail/
Slug/Scratch proteins; (b) Gfi1 and Gfi1-related proteins; and
(c) Mlt1 and Insm1 proteins. The first two subfamilies contain
well-studied transcriptional repressors implicated in a broad
range of developmental processes (morphogenetic cell move-
ments, mesoderm and neural crest formation, epithelial–mesen-
chymal transition, neurogenesis, haematopoiesis…), as well as
in tumor progression (Grimes et al., 1996; Sefton et al., 1998;
Tong et al., 1998; Stegmann et al., 1999; Nakakura et al., 2001a,
b; McGee et al., 2003; Hock et al., 2004; Takahashi et al., 2004;
Ashraf et al., 2004; Park et al., 2005; Wu et al., 2005; Fiolka
et al., 2006).
The third group consists of two intronless genes, Mlt1 and
Insm1, about which much less is known. Mlt1 is expressed in
several normal tissues and is silenced by methylation in liver
tumors of MT-D2 mice, suggesting that it functions as a growth
or tumor suppressor in liver cells, and possibly also in certain
neurones (Tateno et al., 2001). Insm1 was isolated from a
human insulinoma subtraction library (Goto et al., 1992). It is
strongly expressed in the developing pancreas, during early
Central Nervous System (CNS) development, and in tumours of
neuroendocrine origin (Goto et al., 1992; Lan et al., 1993;
Breslin et al., 2003; Lukowski et al., 2006) but not in most non-
neuroendocrine tumors, nor in normal adult tissues (Lan et al.,
1994; Li et al., 1997). Insm1 is a target gene for NeuroD1
regulation (and vice versa), suggesting that Insm1 may play a
role during neurogenesis and pancreas organogenesis (Breslin et
al., 2002, 2003). It has also been recently reported to be a target
of Neurogenin3 and to be required for normal differentiation of
pancreatic endocrine cells in vitro (Mellitzer et al., 2006). The
role(s) of mammalian Insm1 proteins in vivo, and especially in
normal CNS development, remains to be clarified.
To further characterise Ol-insm1 genes, we performed de-
tailed expression and gain-of-function studies. We also per-
formed a clonal ectopic expression analysis and tested the effects
of deleted forms of Ol-insm1b. Our results clearly point to a
previously unravelled role of this gene as a cell cycle arrest factor
and shed some light on the molecular mechanism by which this
gene is regulating cell cycle withdrawal.Materials and methods
Fish strains
Medaka embryos and adults of a Carbio strain (kindly provided by Jochen
Wittbrodt, EMBL, Heidelberg, Germany) were used in all experiments.Embryos were collected and incubated in Yamamoto's embryo rearing medium
(Yamamoto, 1975) at 26 °C and staged according to Iwamatsu (1994).
Ol-insm1a and Ol-insm1b cloning
Ol-insm1a and Ol-insm1b were isolated from a cDNA library of medaka
embryonic brain (Nguyên et al., 2001b). cDNA was used as template for PCR
amplification of the Ol-insm1a and Ol-insm1b coding regions, using the
following primers: pRN3L-insm1a: CGGAATTCCAGCTGTCAGACCACCG-
CGAACATG; pRN3R-insm1a: ATAGTTTAGCGGCCGCGCTGGTCACGA-
ATCATGTGTGAACAGTCCCGG; pRN3L-insm1b: 5′CGGAATT-
CCCATCTCCCCAAAGTGCCTTTCTGC3 ′ ; pRN3R-insm1b: 5 ′
ATAGTTTAGCGGCCGCCCTCCATTAAAGGCACGAGTTCTGTGTT3′.
DNA fragments of ∼1400 bp for Ol-insm1a and ∼1600 bp for Ol-insm1b
were purified with QiaexII (Qiagen, Germany), subcloned into pCRII-TOPO
(Invitrogen, CA, USA) and sequenced. These fragments were then excised by
digestion with EcoRI and NotI and subcloned into pBluescript-RN3 (Lemaire
et al., 1995) to obtain pRN3-insm1a and pRN3-insm1b.
Sequence analysis
Phylogenetic analyses including the calculation of bootstrap values were
done using CLUSTAL W 1.83 at http://www.genebee.msu.su/clustal (Thomp-
son et al., 1994), PHYLIP (Retief, 2000) and GeneBee Phylogenetic Tree
Prediction at http://www.genebee.msu.su/services/phtree_reduced.html. Cluster
algorithms were used to construct the phylogenetic tree. In the bootstrap the
multiple alignment was resampled 100 times.
Whole-mount in situ hybridisation (WMISH)
Sense and antisense digoxigenin-UTP probes were prepared according to
Joly et al. (1997). WMISH procedure was performed as described in Deyts et al.
(2005). Control sense probes did not lead to any detectable signal. Whole em-
bryos were mounted in 1% methylcellulose (Sigma). For histological analysis,
stained embryos were embedded in wax, sectioned at 8 μm on a rotary micro-
tome and counterstained with Nuclear Fast Red.
I-SceI meganuclease-mediated transgenesis
The α1T1pEGFP fusion vector (Hieber et al., 1998) was used to map the
functional domains of Ol-Insm1b. Various constructs flanked by I-SceI recog-
nition sites were injected together with the I-SceI meganuclease into one-cell
stage medaka embryos as described in Thermes et al. (2002). The following
DNA constructs were made: α1T1p-insm1b (full sequence) and α1T1p-VENUS-
insm1b (adding the full sequence coding the fluorescent protein VENUS; Nagai
et al., 2002). α1T1p-insm1b construct was made by restriction endonuclease
digestion of pRN3-insm1b and subcloned in frame with the α1T1p-coding
sequence. The VENUS insert was generated by PCR amplification from pCS2-
VENUS and subcloned in fusion with Ol-insm1b. Clones were verified by
sequencing.
Fertilised eggs were injected with 10 ng/μl and 15 ng/μl of α1T1p-VENUS-Ol-
insm1. For injection, embryos were placed in rows of square-shaped channels
made with plastic casts in 1% agarose and kept inside after injection to preserve
them ordered. At stage 17 (25 h post-fertilisation; hpf) they were scored and
noted for fluorescence. At stage 29 (72 hpf) they were independently (blindly)
scored and noted for phenotype.
mRNA microinjections
pRN3-insm1a and pRN3-insm1b were linearised with NotI and transcribed
in vitro with T3 RNA polymerase using the mMESSAGE mMACHINE kit
(Ambion, Applied Biosystems, CA, USA). Following DNAse treatment, RNA
was purified with the RNeasy Kit (Qiagen, Germany).
Variable amounts of Ol-ism1a and Ol-insm1b mRNA, from 450 to 650 ng/
μl, were injected into one blastomere at the one-cell stage. Doses lower than
200 ng/μl had no detectable effect on embryonic development. Doses up to
1300 ng/μl had no lethal effects. After injection, embryos were returned at
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control solutions.
Clonal analyses were performed by injecting of Ol-insm1b mRNA (500 ng/
μl) in a central blastomere at the 32-cell stage. Control embryos were injected
with 0.8 μg/μl of MO-insm1b-CF alone.
DAPI staining
Pre- and post-mid-blastula transition (MBT) embryos were fixed for 2 h in
4% paraformaldehyde (PFA) and dechorionated, and blastoderm was separated
from the yolk. Before MBT, cells were counted with the Metamorph® Imaging
System software, following incubation with DAPI (Sigma; 300 nM in PBS for
30 min). After MBT, DAPI-stained cells were microscopically analysed for
evidence of apoptosis.
TUNEL assay
VENUS-Ol-insm1bmRNA (500 ng/μl; see below for mRNA transcription and
recovery) was injected in one blastomere at the two-cell stage. Development of
injected embryos was arrested at 9 hpf (stage 11; MBT) by fixation with 4% PFA
and glutaraldehyde 0.05% for 48 h at 4 °C. Embryos were mechanically
dechorionated in PBS and in toto analysed for apoptosis. Fixed-embryos were
permeabilised with 0.1% sodium citrate, labelled for DNA strand breaks using
the In Situ Cell Death Detection kit (TUNEL, Roche Molecular Biochemicals).
Staining substrate was Fast Red (Roche Molecular Biochemicals). Whole
embryos were observed under a Leica MZFL III dissecting microscope.
Morpholinos experiments
A fluorescein-conjugated antisense morpholino oligonucleotide (MO-
insm1b-F: 5′TTTTTACCAGGAATCCTTTGGGCAT3′) was designed to target
the sequence containing the initiation codon of Ol-insm1b (Gene Tools, USA).
Various amounts of MO (from 4 to 16 μg/μl) were injected into one blastomere
of one-cell stage embryos. A mispaired morpholino (MO-insm1b-CF: 3′TTTTT-
A__GCA__CGAAT__GCTTT__CGG__GAT5′; mispaired bases are underlined) was used
as control.
Flow cytometry
Ol-insm1b mRNA-injected and uninjected embryos were frozen in liquid
nitrogen at MBT (stage 10) and dechorionated in Galbraith buffer (Galbraith et
al., 1983). Nuclei were separated from debris by filtration through a 50-μm
nylon mesh. Filtrates were treated with RNase A (100 μg/ml) and stained with
10 μg/ml DAPI (Sigma). Nuclei (3.000) were analysed with an EPICS Elite ESP
flow cytometer. Nuclei from adult medaka liver cells (G1 arrested) were used for
calibration of the 2N DNA population. DNA content histograms were resolved
by the MultiCycle AV software. Histograms were obtained usingMultiCycle AV
software.
Functional domains deletions and fusion proteins
Deletions of Ol-insm1b were prepared: (1) pRN3-insm1bΔSNAG (lacking
three of the seven amino acids of the SNAG domain) was obtained by enzyme
restriction of pRN3-insm1b with XcmI and SmaI. (2) pRN3-insm1bΔNH2
(deletion of 207 amino acids of the amino-terminal half containing the SNAG
domain) was generated by PCR amplification from pCRII-TOPO-Ol-insm1b
using the following primers: pRN3La-insm1bΔNH2: 5′GAATTCGCCACCAT-
GCTCGGGCTCAAAATCAAAGAGGGG3′ and pRN3Ra-insm1b: 5′ATAGT-
TTAGCGGCCGCCCTCCATTAAAGGCACGAGTTCTGTGTT3′; the
fragment was excised with EcoRI and NotI and cloned into pBluescript-
RN3. (3) pRN3-insm1bΔzf1–2 (which lacks the first two zinc-finger domains)
was obtained by enzyme restriction of pRN3-insm1b with BsiWI and NdeI. (4)
pRN3-insm1bΔzf1–5 (lacking the carboxyl-terminal half containing the five
zinc-finger domains) was generated by enzyme restriction of pRN3-insm1b
with BsiWI and NotI. Plasmids linearisation, in vitro transcription, mRNA
recovery and mRNA microinjections were performed as described above.Fusion proteins were obtained from the following constructs: (1) pRN3-
VENUS-Ol-insm1b; the VENUS-Ol-insm1b fragment was excised from α1T1p-
VENUS-insm1b with BamHI and NotI and cloned into pBluescript-RN3. (2)
pRN3-VENUS-Ol-insm1bΔNH2; VENUS was excised from pRN3-VENUS-Ol-
insm1b with BstY and AgeI and subcloned in frame into pRN3-insm1bΔNH2.
(3) pRN3-VENUS-Ol-insm1bΔzf1–2 was obtained by enzyme restriction of
pRN3-VENUS-Ol-insm1b with BsiWI and NdeI. Plasmids were linearised with
KpnI, in vitro transcribed with the mMESSAGE mMACHINE T3 kit (Ambion,
Applied Biosystems, CA, USA), the RNA was lithium chloride precipitated
following manufacturer's instructions, and mRNA microinjections were
performed as described above.Results
Cloning and sequence analysis
In the course of a WMISH screen on the medaka OT (Ngu-
yên et al., 2001b; Deyts et al., 2005), we isolated two poorly
characterised genes that exhibited a strong expression in the OT
arrest zone: CDOL_001_1270 and CDOL_000_0598, the pre-
dicted products of which were 56.4% identical at the amino acid
level. BLAST search analyses showed that CDOL_001_1270 is
similar to mouse and human insulinoma-associated 1 (Insm1;
formerly IA-1) intronless proteins (48.7% and 52.7% identity).
CDOL_000_0598 is also similar to these mammalian proteins
(46.4% and 49.4% identity). We thus named these genes Ol-
insm1a and Ol-insm1b, respectively. The vertebrate Insm1
family also contains two zebrafish members (Dr-Insm1a and
Dr-Insm1b) that are 63.3% and 60.9% identical to Ol-Insm1a
and Ol-Insm1b. Insm1 belongs to a highly conserved subgroup
of zinc-finger proteins, the SNAG transcriptional repressor
family (Fig. 1A), characterised by a seven amino acid SNAG
repressor motif in the NH2 terminal and four-to-six C2H2-type
zinc-finger motifs in the COOH-terminal half (Fig. 1B).
The SNAG family consists of 20 proteins (Tateno et al.,
2001). A survey of available protein databases unravelled two
additional members (Scratch 1 and Scratch 2). Two other
members were recently described in zebrafish (Dr-Insm1a and
Dr-Inms1b; Lukowski et al., 2006). Fig. 1A shows the
phylogenetic relationship amongst SNAG proteins (the analysis
of their full sequences was made as described in Materials and
methods). The resulting tree indicates that the SNAG family is
made of three subfamilies: (a) Snail/Slug and Scratch proteins,
(b) Gfi1 proteins and (c) Insm1/Mlt1 proteins. Fig. 1B shows
the multiple alignments of Ol-Insm1b and Ol-Insm1a with other
reported members of the Insm1/Mlt1 subfamily.
Ol-insm1b expression pattern in embryos and adult CNS
This study is focussed on Ol-insm1b: indeed, in our func-
tional analysis Ol-insm1a appeared to behave in a similar albeit
weaker way than Ol-insm1b (see below).
Ol-insm1b transcripts are not detected during early cleavages
and gastrula stages, when all cells proliferate actively, neither by
WMISH nor by real-time PCR analysis (data not shown). Ol-
insm1b is first detected in the rostral pole at early neurula stage
(stage 18; optic bud formation) (Fig. 2A). Ol-insm1b expression
then increases throughout the brain, especially in the telen-
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At stages 28 and 30 (30 and 35 somites; Figs. 2C, D and G–I),
Ol-insm1b is highly expressed in the telencephalon (Fig. 2G), inFig. 1. (A) Phylogenetic tree of the SNAG family; SNAG proteins are subdivided
(B) Multiple alignments of Ol-Insm1a and Ol-Insm1b with members of the Insm1/M
Phylogenetic analysis was done using CLUSTAL W 1.83 with a PHYLIP output fo
GeneBee page (see Materials and methods for details). Bootstrap values are exprethe OT and midbrain tegmentum (Figs. 2H, I) and in the
hindbrain, where it is expressed in a characteristic banded
pattern (Figs. 2C, D, H). At these stages, Ol-insm1b is stronglyin three subfamilies: Gfi1-related, Snail/Slug/Scratch and Mlt1/Insm1 proteins.
lt1 subfamily. Conserved SNAG, NLS and zinc-finger domains are indicated.
rmat. Cluster algorithms were applied to construct the phylogenetic tree at the
ssed in percentages and placed at nodes.
Fig. 2. Expression pattern of Ol-insm1b after ISH in whole-mount embryos (A–F), and in sagittal (H, I) and transverse (G, J–P) sections of medaka embryos at the
indicated stages. Arrow in (A) indicates Ol-insm1b expression in the rostral pole of the embryo. Arrowheads in (B–D, H) indicate Ol-insm1b expression in the
rhombic lips. Arrows in (E, F, N, P) indicate the arrest zone of the optic tectum. Arrow in (I) indicates Ol-insm1b expression in the pancreas. Stars in (I, P) indicate the
proliferative zones of the retina and OT. DZ, differentiation zone; h, habenula; Hy, hypothalamus, M, midbrain; OB, olfactory bulb; OT, optic tectum, PO, preoptic
area; pt, pretectum; PT, posterior tubercule; PZ, proliferation zone; t, telencephalon; TgM, tegmentum; Th, thalamus.
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it is also present in some scattered cells in the central area of the
OT where the first signs of differentiation appear (Fig. 2H). In
the retina, Ol-insm1b is widely expressed throughout the differ-
entiating zone, absent from the marginal proliferative zone and
from the most mature central (already differentiated) zone of the
retina (Fig. 2I). Outside the brain, Ol-insm1b is strongly ex-
pressed in the pancreas (Fig. 2I). Neural Ol-insm1b expression
decreases as development proceeds and cells differentiate (Fig.
2E). In transverse sections through the brain at stage 32 (34–35
somites; Figs. 2E and J–P), Ol-insm1b is detected in the
olfactory bulbs and in the telencephalon (especially in its ventralarea; Fig. 2J), in pretectal, thalamic and preoptic regions (Figs.
2K, M, O), in the primordial right and left habenula (Figs. 2C–
F), in the suprachiasmaticus nucleus, in the posterior tubercle
(Fig. 2M), in the rostral and caudal hypothalamus (Figs. 2N, O),
in some midbrain–tegmentum nuclei (Fig. 2N), in the torus
semicircularis and in a small number of hindbrain nuclei. In the
OT (Fig. 2P), Ol-insm1b expression is restricted to the limit
between the proliferative and post-mitotic zones and absent
from proliferating cells in its caudal, ventrolateral and dorso-
medial margins. The same pattern is observed in the retina (Fig.
2L), where mRNA is located at the border between the mature
central retina and the marginal proliferative zone. Ol-insm1b
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cially in the hindbrain.
Ol-insm1b is also strongly expressed in the adult brain (Figs.
3A, B); it generally remains expressed in the domains where it
showed an embryonic expression and is turned on in some
additional territories (Figs. 3C–K). Series of horizontal, sagittalFig. 3. Expression pattern ofOl-insm1b in adult medaka brain after WMISH in dorsal
in F) sections. Labelled cells are found in the olfactory bulbs and in both the ventral an
thalamic and pretectal regions (E–G), in the left habenula (where Ol-insm1bmRNA i
2C–F showing a symmetrical habenular expression ofOl-insm1b during embryonic de
hypothalamus (G–I); Ol-insm1bmRNA is also detected in some midbrain–tegmentum
the torus semicircularis and in the limit between the proliferative and post-mitotic zon
small number of hindbrain nuclei (K). Arrow in (F) indicates the asymmetrical labellin
anterior nucleus of the diencephalon; CbSg, granular stratum of CCb; CCb, cerebellar
telencephalon; Hc, periventricular caudal hypothalamus; Hd, dorsal habenula; HD, per
inner cellular layer of the OB; IR, inferior rectus of nucleus of the oculomotor ne
hypothalamic anterior lobe; nFS, nucleus of the fasciculus solitarius; NGp, posterio
tectum; PMp, preoptic magnocellular posterior nucleus; PPa, preoptic parvocellula
tubercle; RL, rostrolateral nucleus of the diencephalon; SC, suprachiasmatic nucleus;
telencephalon; VL, ventrolateral nucleus of the diencephalon; Vp, posterior area of tand transverse sections allowed us to observe labelled cells in
the olfactory bulbs and in both the ventral and dorsal telen-
cephalon (Figs. 3C–E), in the suprachiasmaticus nucleus (Fig.
3E), in preoptic, thalamic and pretectal regions (Figs. 3E–G).
Ol-insm1b shows a peculiar asymmetric expression in the
adult habenula (left side only), whereas it is expressed sym-(A) or ventral view (B), and in sagittal (J), transverse (C–I, K) or horizontal (inset
d dorsal telencephalon (C–E), in the suprachiasmaticus nucleus (E), in preoptic,
s strongly and asymmetrically expressed; F and inset within; compare with Figs.
velopment), in the anterior and posterior tubercle (H) and in the rostral and caudal
nuclei (H); in the dorsal midbrain,Ol-insm1bmRNA expression is observed in
es of the OT (H, I);Ol-insm1bmRNA is observed in the cerebellum (I, J) and in a
g in the left habenula. Arrows in (I) indicate the arrest zone of the optic tectum. A,
body; Dlp, area lateroposterior of the diencephalon; Dm, area medial of the dorsal
iventricular dorsal hypothalamus; HV, periventricular ventral hypothalamus; ICL,
rve; LH, lateral nucleus of the hypothalamus; NDIL, nucleus diffusus of the
r glomerulosus nucleus; nIX, nucleus of the glosso-pharingeal nerve; OT, optic
r anterior nucleus; PPp, preoptic parvocellular posterior nucleus; PT, posterior
TL, torus longitudinalis; TS, torus semicircularis; Vd, dorsal area of the ventral
he ventral telencephalon; Vv, ventral area of the ventral telencephalon.
Table 1
Late dose-dependent effects of Ol-insm1b on development (transient transgenesis
experiments)
Phenotype (stage 29)







Absent 95.2% 4.8% 0
Weak 0 44.4% 55.6%
Strong 0 16.7% 83.3%
15 ng/μl
n=29
Absent 81.8% 18.2% 0
Weak 0 63.6% 36.4%
Strong 0 0 100%
Values indicate the percentage of embryos of each phenotype showing none,
weak or strong transgene expression after injection of α1T1p-VENUS-Ol-insm1b.
A statistically significant relation was found between the strength of fluo-
rescence and the severity of altered phenotype after MBT (Pb0.0005, Chi-
square test). n: number of injected embryos.
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2C–F with Figs. 3A, F and inset within). Ol-insm1b mRNA is
also expressed in the anterior and posterior tubercle (Fig. 3H)
and in the rostral and caudal hypothalamus (Figs. 3H, I); Ol-
insm1b mRNA is also detected in some midbrain–tegmentum
nuclei (Figs. 3H, I); in the dorsal midbrain, Ol-insm1b mRNA
expression is observed in the torus semicircularis and in the
limit between the proliferative and post-mitotic zones of the OT
(Fig. 3H); Ol-insm1b mRNA is observed in the cerebellum
(Figs. 3I, J) and in a small number of hindbrain nuclei (Fig. 3K).
By analogy with genes previously characterised (Nguyên et
al., 2001a,b; Candal et al., 2004, 2005a), the continued ex-
pression of Ol-insm1b at the border between the mature central
zone and the marginal proliferative zone of both the OT and the
retina strongly suggested that Ol-insm1b was potentially in-
volved in negative growth control in the nervous system. We
began the analysis of its function by attempting to inhibit its
expression with morpholinos. We got no detectable effects
whatsoever on cell cycle rate and number of cells after one-cell
stage injection of the vehicle solution only, after injection of the
specific morpholino MO-insm1b-F at 8 μg/μl or after injection
of the mismatch morpholino MO-insm1b-CF at the same con-
centration (data not shown).
We thus turned to ectopic expression experiments and began
by attempting to express Ol-insm1b in proliferating cells of the
nervous system.
Ol-insm1b affects late embryonic neural development
To ectopically express Ol-insm1b in the developing medaka
nervous system, we used I-SceI meganuclease-mediated trans-
genesis, the high efficiency of which allows analysing the
effects of overexpression of a particular gene in mosaic (F0)
injected embryos, without establishing stable transgenic fish
lines. This method has proven to be quick, powerful and amen-
able to quantification in fish and amphibian models (Thermes et
al., 2002; Grabher et al., 2004; Pan et al., 2006; Ogino et al.,
2006). We injected fertilised eggs with 10 ng/μl of a DNA
construct (α1T1p-VENUS-Ol-insm1b) where the expression of a
VENUS-Ol-Insm1b transgene is driven by the α1-tubulin
promoter, which directs expression specifically in the prolifer-
ating neural progenitors (Gloster et al., 1994, 1999). A mosaic
expression of VENUS-Ol-insm1b was first observed at the begin-
ning of neurulation (25 h post-fertilisation (hpf), stage 17),
when the promoter becomes active. Embryos were grouped in
three classes according to the amount of fluorescent, transgene-
expressing cells in the central nervous system. Embryos show-
ing no VENUS-Ol-Insm1b-expressing cells were classified as
negative (“absent”); embryos in which only a small amount of
cells expressed VENUS-Ol-Insm1b were classified as “weak”;
embryos with an almost ubiquitous VENUS-Ol-Insm1b expres-
sion in the nervous system were classified as “strong”. They
were allowed to develop up to stage 29 (72 hpf) and their phe-
notypes recorded (see Table 1). Embryos were judged to be
“small” or to “have brain malformations” when they were re-
duced in size or showed altered and/or delayed development
with respect to normal embryos (Candal et al., 2005c; Candal,2002). Most embryos showing no fluorescence at the beginning
of neurulation developed normally (95.2%; Table 1 and Figs.
4A, B), and only a small percentage was reduced in size (4.8%),
without severe brain malformations. None of the embryos
showing a weak transgene expression developed normally,
44.4% were reduced in size and 55.6% showed additional brain
abnormalities (Table 1). Among the embryos exhibiting a strong
transgene expression, 16.7% showed a reduction in size and no
brain abnormalities, whilst 83.3% exhibited size reduction and
severe brain anomalies (Table 1 and Figs. 4C, D). This effect
was dose-dependent since the percentage of embryos showing
both reduction in size and critical brain malformations increased
when 15 ng/μl of α1T1p-VENUS-Ol-insm1b was injected at the
one-cell stage (see Table 1).
Since the main result of these experiments is an overall
reduction in CNS size following Ol-insm1b over-expression in
neural progenitors, it further points to a role of this gene in
negative cell cycle control in brain development. To analyse this
effect in more details, we turned to mRNA injections in early
embryos. This method can also be used to evaluate the role of
the different domains of a molecule. Given the stability of the
mRNAs in such experiments, we expected to observe differ-
ences between injected and control embryos at about the stage
when Ol-insm1b is normally expressed, i.e., at early neurula.
Ectopic expression of Ol-insm1b causes cell cycle arrest in
early embryos
Ol-insm1b mRNA (500 ng/μl) was injected at the one-cell
stage and a developmental delay was observed (Table 2 and Fig.
5). At 2.5 hpf (stage 5; 8-cell stage), 71.4% of mRNA-injected
embryos were delayed (n=207). To quantify the degree of delay
in cell divisions, embryos were allowed to develop at 26 °C
after injection, and cell numbers were counted from stage 4
(2 hpf; four-cell stage) until stage 9 (6 hpf; about 512 blasto-
meres in control embryos).
The number of cells in delayed embryos was significantly
reduced when compared to control embryos, which divided
normally (Table 2 and Figs. 5A, B). Moreover, cells in the
Fig. 5. Ectopic Ol-insm1b expression causes cell cycle delay. (A, B) Dorsal
views of early embryos (3 hpf). In the Ol-insm1b mRNA-injected embryos (B),
the number of cells is reduced and cells are larger respective to control embryos
(A). (C, D) DAPI staining at the late blastula stage (9 hpf). The number of cells is
reduced in the Ol-insm1b mRNA-injected embryos, without evidence of cell
death. (E, F) TUNEL staining at the late blastula stage (9 hpf). Fast Red-stained
(apoptotic) cells were only observed in extra-embryonic tissues (E); VENUS-Ol-
Insm1b expressing cells (in green) are devoid of Fast Red staining (F). (G)
Percentage of divergence in numbers of cells obtained after injection of different
Fig. 4. Ol-insm1b affects medaka development. After α1T1p-VENUS-Ol-insm1b
injection, embryos at stage 17 (25 hpf) were grouped according to transgene
expression: absent (A, bright field), weak (not shown) or strong (C). Most of
non-fluorescent embryos developed normally until stage 29 (72 hpf, B), whereas
all strongly transgene-expressing embryos displayed severe brain anomalies
and/or became reduced in size (D).
8 E. Candal et al. / Developmental Biology 309 (2007) 1–17mRNA-injected embryos were larger. Divergence in the number
of cells between Ol-insm1b mRNA- and control-injected em-
bryos increased as development proceeded (100% of embryos
were delayed at 4 hpf, n=175; Table 2). At 6 hpf (stage 9), both
Ol-insm1b mRNA and BSS injected embryos were fixed,
stained with DAPI, and nuclei were counted.Ol-insm1bmRNA-
injected embryos showed a severe decrease in cell number, as
compared with control embryos (276±20.3 versus 539±21.7;
Table 2; see also Figs. 5C, D at 9 hpf).
To determine if Ol-Insm1b induced apoptosis, injected em-
bryos were allowed to develop until stage 11 (9 hpf, late blas-
tula) when apoptotic pathways become active (Hensey and
Gautier, 1997; Carter and Sible, 2003). They were stained with
DAPI that allow identification of chromatin condensation, nuc-
lear shrinkage and formation of apoptotic bodies (Huynh andTable 2
Ectopic expression of Ol-insm1b during pre-MBT development
2.5 hpf (st. 5),
n=207 a
4 hpf (st. 8),
n=175 b
6 hpf (st. 9),
n=177 c




Values indicate the mean number of cells (with standard deviations) as computed
in Ol-insm1b mRNA-injected and control (BSS-injected) embryos at different
developmental stages. Differences amongst Ol-insm1b mRNA-injected and
control embryos were significant (Pb0.0001, Student's t test) for each point of
observation (in hours post-fertilisation; hpf). n: total number of injected
embryos.
a 207 from 290 embryos (71.4%) were retarded.
b 175 from 175 embryos (100%) were retarded.
c 177 from 177 embryos (100%) were retarded.
concentrations of Ol-insm1bmRNA: the effect of Ol-insm1b is dose-dependent.Teel, 2000; Zong et al., 2003; Candal et al., 2004, 2005b). No
signs of apoptosis were ever detected (Figs. 5C, D).
Injected embryos were additionally injected with VENUS-Ol-
insm1b mRNA (a construct that allows direct observation of the
mRNA transcripts; see results below) and analysed for apop-
tosis by the TUNEL method as described in Materials and
methods. No apoptosis above basal levels was detected at 9 hpf
neither in wild-type-like embryos (data not shown) nor in Ol-
insm1b mRNA-injected embryos, although the level of apop-
tosis was slightly increased in extra-embryonic tissues (Figs.
5E, F).
We then tested the effect of increasing amounts of Ol-insm1b
mRNA at different embryonic stages (Fig. 5G). The percentage
9E. Candal et al. / Developmental Biology 309 (2007) 1–17of divergence was calculated as [(nC−nRi) /nC]×100, where
nC is the mean number of cells in control embryos and nRi is
the mean number of cells in Ol-insm1b mRNA-injected em-
bryos. Divergence in the number of cells between Ol-insm1b
mRNA- and control-injected embryos increased as develop-
ment proceeded and this effect was clearly dose-dependent.
We examined the effects of these Ol-insm1b injections on
late development. Injected embryos progressed through gas-
trulation but their development was severely affected: when
compared with control embryos (Figs. 6A, B) they exhibited a
delayed epiboly at 18 hpf (stage 15, Fig. 6C) and a reduced size
at 42 hpf (stage 23, Fig. 6D), probably as a consequence of the
early decrease in cell number.
A similar analysis was performed by injecting Ol-insm1a
mRNA (500 ng/μl). Early cleavages were also affected, but to a
lesser extent, as shown by the reduction in cell numbers: 346±
57 for Ol-insm1a mRNA versus 276±29 for Ol-insm1b mRNA
injection, at the same dose and the same developmental stage
(6 hpf; stage 9; data not shown). Since Ol-insm1a appeared to
have similar (but weaker) effects on cell division, all assays
were carried out with Ol-insm1b.
Specificity of Ol-insm1b mRNA effect
Wewondered whether this strong anti-proliferative effect was
specific to Ol-insm1b (and Ol-insm1a) or was shared by other
genes of the SNAG family, the functions of which are rather
poorly documented. We thus cloned Ol-Mlt1, the medaka
homologue of the mouse Mlt1, which represents the “closest
relative” to the Ol-insm1 genes in the SNAG family (see Fig. 1).
Ol-Mlt1 mRNA was injected at the one-cell stage in the same
conditions as described above for Ol-insm1b. Embryos were
monitored from 2 hpf to 6 hpf, and from the beginning ofFig. 6. Control experiments with EGFP mRNA. No effects on early cleavages, nor l
Embryos coinjected with Ol-insm1b mRNA displayed a delayed epiboly (C) and aneurulation onwards. No significant differences in cell numbers
were observed between Ol-Mlt1 mRNA-injected embryos and
controls (data not shown), suggesting that the effect on cell cycle
arrest observed in Ol-insm1b (and Ol-insm1a) mRNA-injected
embryos is not common to all C2H2-containing proteins.
Clonal analysis of Ol-insm1b mRNA-injected embryos
Clonal analysis was performed by injecting Ol-insm1b
mRNA in a single central blastomere at the 32-cell stage. The
central blastomeres, which produce the embryo proper, are not
specified at this stage (except for the germ line precursors) and
proliferate actively until MBT (Thermes et al., 2006 and
references therein). This experiment allowed us to follow the
behaviour of Ol-insm1b mRNA expressing clones in a normal
context. To follow the progeny of Ol-insm1b mRNA-injected
cells, we coinjected the fluorescein-coupled control mismatch
MO (MO-insm1b-CF, 0.8 μl/ml). We used this marker instead
of EGFP mRNA to avoid the delay due to the translation of
EGFP into protein. Both Ol-insm1b mRNA-injected and
control (injected with MO-insm1b-CF alone) embryos were
fixed 3 and 8 h post-injection (hpi) and counterstained with
DAPI. At 3 hpi the number of cells inOl-insm1b-injected clones
was significantly reduced (and their size larger) when compared
to control clones (in 95.6% of embryos, where 6.75±3 versus
37.4±8.5 cells were counted; n=58; Figs. 7A, C). At 8 hpi, the
blastoderm covered about one half of the yolk sphere in both
control and Ol-insm1b-injected embryos. The fluorescent
cells were uniformly distributed throughout the embryo in
control embryos (Fig. 7B) whereas, in Ol-insm1b-injected
embryos, the number of fluorescent cells was strongly
reduced and their distribution was not uniform throughout
the blastoderm (Fig. 7D).ate morphological changes were observed after EGFP mRNA injections (A, B).
reduced size (D).
Fig. 7. Clonal analysis by injection of Ol-insm1b mRNA in a single central blastomere at the 32-cell stage. A clone of cells issued from a single Ol-insm1b mRNA-
injected blastomere (500 ng/μl) contains fewer cells (C, D) than a control one (A, B). Ol-insm1b mRNA- and control-injected embryos were coinjected with the
fluorescein-coupled control MO (MO-insm1b-CF, green). Cells were counterstained with DAPI (blue).
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Ol-insm1b mRNA-injected (at the one-cell stage) embryos
were analysed for DNA content by flow cytometry just after
the mid-blastula transition (MBT; stage 11), i.e., when cell
cycles become asynchronous, interphases of the cycle (G1 and
G2) become detectable and apoptotic pathways become active
(Fig. 8). In control embryos, nuclei were either uniformlyFig. 8. Flow cytometric DNA content analysis in embryos after the MBT. DNA conten
in Ol-insm1b mRNA-injected embryos (right). Ol-insm1b-mRNA injection results indistributed between 2N and 4N (i.e., in S phase; 55.3%) or
contained 4N DNA (corresponding to cells in G2+M phase;
39.5%); a small percentage also contained 2N DNA,
corresponding to cells in G1 phase (5.2%). In Ol-insm1b
mRNA-injected embryos, we observed a decreased percentage
of nuclei in S phase (25.6%) and an increased percentage of
nuclei in G2+M (52.3%) and G1 (22.2%), suggesting a
general shift away from proliferation.t histograms in a suspension of nuclei from uninjected control embryos (left) and
an increase in the percentage of cells in G1 and G2, and a decrease of cells in S.
Table 3
Effect of deletion of conserved functional domains during pre-MBT development
3 hpf (st. 6) 5 hpf (st. 8)
BSS 18.6±1.92 111.9±6.26
ΔSNAG mRNA 500 ng/μl, n=63 8.3±0.96 65.1±9.6
Δzf1–5 mRNA 500 ng/μl, n=38 17.2±3.13 107.7±5.91
Δzf1–2 mRNA 500 ng/μl, n=84 18.3±1.84 109.9±7.97
Values indicate the mean number of cells (with standard deviations) as computed
in embryos injected as indicated in the left column. For each point of observation
(in hours post-fertilisation; hpf), significant differences with control embryos
(Pb0.0001, Student's t test) were only detected after injection of Ol-
insm1bΔSNAG mRNA. n: total number of injected embryos.
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content inferior to 2N) were detected. These results suggest that
Ol-insm1b affects cell proliferation since the number of cells is
decreased without evidence of cell death.
Roles of the SNAG and zinc-finger domains in cell cycle arrest
before MBT
To determine which of Ol-Insm1b conserved functional do-
mains are critical for cell cycle arrest, we modified the Ol-
insm1b sequence by deleting either the SNAG domain or the
zinc-finger domains.
Embryos were injected at the one-cell stage with variable
amounts of Ol-insm1bΔSNAG mRNA (from 340 ng/μl to
1 μg/μl). Injection of 400 ng/μl of Ol-insm1bΔSNAG caused
cell cycle arrest during the first cell cleavages (in 95.2% of
embryos, n=62; Figs. 9A, B). For comparison with Ol-insm1b
mRNA injections, embryos were then injected with 500 ng/μl
of Ol-insm1bΔSNAG (n=63) and cells counted at 3 hpf and
5 hpf. Significant differences with cell numbers in control
embryos were observed (see Table 3).
Comparable results were obtained when similar amounts of
Ol-insm1bΔNH2 mRNA (lacking 207 residues in the NH2-
terminus) were injected at the one-cell stage (not shown). Both
Ol-insm1bΔSNAG and Ol-insm1bΔNH2 constructs thus
mimic the effect observed with the full-sequence Ol-insm1b,
suggesting that the NH2-terminal domain is dispensable for the
inhibition of cell division.Fig. 9. Control embryos (A, C, E, G) and embryos injected with modified Ol-insm1b
Ol-insm1bΔSNAG results in cell cycle arrest during the first cell cleavages. (D) Injec
differences between Ol-insm1bΔzf1–2 mRNA-injected and control embryos were ne
embryos were reduced in size (H) or showed morphological defects (I).500 ng/μl of Ol-insm1bΔzf1–5 mRNAwas then injected at
the one-cell stage (either alone or coinjected with 500 ng/μl of
EGFP mRNA). The number of cells in Ol-insm1bΔzf1–5 in-
jected embryos was not statistically different from that observed
in control embryos (Table 3), suggesting that zinc-finger do-
mains are necessary to arrest the cell cycle before MBT. Im-
portantly, late morphological changes (after MBT) were very
rarely observed and not statistically significant (Figs. 9C, D and
Table 4).
We then examined whether all zinc-finger domains were
necessary to arrest cell cycle. It has been shown that zinc-finger 2
of the human IA-1 protein is critical for its DNA binding activity
(Breslin et al., 2003). Ol-insm1bΔzf1–2 mRNA was prepared
by deletion of the first and second zinc-finger domains. Variable
amounts of Ol-insm1bΔzf1–2 mRNAwere injected at the one-sequences lacking different functional domains (B, D, F, H, I). (B) Injection of
tion of Ol-insm1bΔzf1–5 mRNA does not affect development. (E, F) Significant
ver detected before MBT. (G–I) After MBT, Ol-insm1bΔzf1–2 mRNA-injected
Table 4






BSS 100% – –
ΔSNAG mRNA 500 ng/μl, n=63 – 79.4% 20.6%
Δzf1–5 mRNA 500 ng/μl, n=38 97.4% 2.6% –
Δzf1–2 mRNA 375 ng/μl, n=39 20.5% 69.2% 10.3%
Δzf1–2 mRNA 750 ng/μl, n=35 – 82.4% 17.6%
Values indicate the percentage of embryos of each phenotype after injection of
different constructs. A statistically significant relation was found between the
injection of Ol-insm1bΔSNAG mRNA and altered development after MBT
(Pb0.0005, Chi-square test). The same was found after injection of Ol-
insm1bΔzf1–2 mRNA (Pb0.0005, Chi-square test). In contrast, injection ofOl-
insm1bΔzf1–5 mRNA has no statistically significance on embryonic post-MBT
development. n: total number of injected embryos.
12 E. Candal et al. / Developmental Biology 309 (2007) 1–17cell stage (from 375 ng/μl to 1 μg/μl). For comparison, 500 ng/μl
injected and control embryos were allowed to develop, and cells
counted at 3 and 5 hpf (see Table 3). Significant differences
between Ol-insm1bΔzf1–2 mRNA-injected and control
embryos were never detected before MBT (Table 3 and Figs.
9E, F), even when 1 μg/μl of Ol-insm1bΔzf1–2 of mRNAwas
injected (data not shown). Ol-insm1bΔzf1–2 mRNA-injectedFig. 10. (A–E) Injections of VENUS-Ol-insm1bmRNA into one blastomere at the two-
detected in the cytoplasm of only one half of the cells, at stage 9 (5.5 hpf; 512 cells
(11 hpf). Ol-insm1b mRNA is detected in only one half of the cells. (F, G) VENUS-Ol-
Ol-insm1bΔNH2 mRNA spreads uniformly amongst all cells. G and H are higher membryos were then allowed to develop (see Table 4) and ob-
served at 26 hpf (st. 18; early neurula stage) and 48 hpf (stage 24;
16 somites). Embryos injected with 375 ng/μl of Ol-insm1b
Δzf1–2 mRNA were reduced in size and/or showed morpho-
logical defects (Table 4), an effect that therefore cannot be a
simple consequence of early cell cycles arrest. This effect was
dose-dependant since doubling the dose of injected mRNA
increased the severity of the observed phenotype (Figs. 9G–I
and Table 4).
Ol-insm1b injections at the two- or four-cell stage
It has been previously reported that in zebrafish (Kimmel and
Law, 1985), the early cleavages (from one-cell to 16-cell stage)
are partial, with an incomplete separation of blastomeres. Ac-
cordingly, in medaka, both MO-insm1b-F and EGFP-mRNA
spread uniformly amongst all daughter cells when injected in
one blastomere of the two-cell stage or the four-cell stage
embryos. To allow direct observation of Ol-insm1b mRNA
behaviour, we prepared a pRN3-VENUS-Ol-insm1b construct in
which VENUS was fused in frame with the Ol-insm1b sequence.
VENUS-Ol-insm1b mRNA (500 ng/μl) was injected in one
blastomere at the two-cell stage, and embryos monitored from
2 hpf to 6 hpf. Unexpectedly, VENUS-Ol-Insm1b proteins werecell stage. Injected mRNA does not spread in the embryo. (A–C) Fluorescence is
). (D, E) Dorsal views of injected embryos after WMISH performed at stage 12
insm1bΔzf1–2 mRNA is also present in only one half of the cells. (H, I) VENUS-
agnifications of F and I, respectively.
13E. Candal et al. / Developmental Biology 309 (2007) 1–17detected in the cytoplasm of only one half of the cells (Figs.
10A, C). We also observed that the cells derived from the
injected blastomere were larger and less numerous than the cells
deriving from the uninjected blastomere (Figs. 10B, C),
indicating that the VENUS-Ol-Insm1b protein retained the anti-
proliferative activity of Ol-Insm1b described above. Similarly,
when VENUS-Ol-Insm1b mRNA was injected in one blastomere
at the four-cell stage, fluorescence was detected in only one
fourth of the cells (data not shown). Embryos injected at the
two-cell stage were then fixed at 11 hpf (stage 12) and processed
for WMISH using Ol-insm1b mRNA probes. Ol-insm1b
mRNA expression was detected in the cytoplasm of only one
half of cells (Figs. 10D, E). VENUS-Ol-insm1bΔNH2 and VENUS-
Ol-insm1bΔzf1–2 constructs were then injected in one
blastomere at the two-cell. Some embryos were then observed
under fluorescence at different developmental stages and others
were processed for WMISH using Ol-insm1b mRNA probes.
While VENUS-Ol-insm1bΔzf1–2 mRNA was detected in only
one half of cells (Figs. 10F, G), VENUS-Ol-insm1bΔNH2
appeared to spread uniformly amongst all cells (Figs. 10H, I),
suggesting that the 5′ region of Ol-insm1b mRNA coding the
SNAG domain is instrumental in preventing the spread of the
mRNA to the uninjected blastomere.
Discussion
Sequence and structural features
We isolated two medaka cDNA clones (Ol-insm1a and Ol-
insm1b) belonging to the Insm1 (formerly IA-1) family. In all
complete or nearly complete vertebrate genomes a single, in-
tronless, Insm1 gene is present, with the exception of the tele-
osts (Tetradodon nigroviridis, Takifugu rubripes, Danio rerio
and O. latipes, Lukowski et al., 2006 and present study)
which possess two paralogues, reflecting the well-documented
genome duplication in this lineage (Wittbrodt et al., 1998).
This protein family is characterised by the presence of a
SNAG (as present in all Snail/Slug vertebrate proteins; Grimes
et al., 1996) motif at the amino-terminal end and five zinc-
fingers of the Cys2-His2 type at the carboxy-terminal end. Their
SNAG domain (MPKGFLV) is typical of the Mlt1/Insm1
subfamily: in Snail/Slug/Scratch proteins and Gfi1 proteins, the
SNAG domain is MPRSFLV. This domain is essential for the
repressor activity of Gfi1 proteins, independently from the
identity of its fourth amino acid (Grimes et al., 1996). Add-
itionally, a conservative substitution is present in Ol-Insm1b
SNAG (MPKGFLV), as in the zebrafish Dr-Insm1b. A putative
nuclear localisation signal (NLS) upstream of zinc-finger 1 is
present in Ol-Insm1b and Ol-Insm1a, as in all other members of
the Mlt1/Insm1 group, but not in Snail/slug/Scratch or Gfi
proteins. The other recognisable motifs in Ol-Insm1b and Ol-
Insm1a are the zinc-fingers (Miller et al., 1985; Goto et al.,
1992). In Ol-insm1a and Ol-insm1b, as in their mammalian
counterparts, a conserved arginine residue replaces the second
histidine of zinc-finger 1. In addition, the third zinc-finger is
spaced roughly at equal distance from the two tandem repeated
zinc-finger motifs located at each side, a feature that maysuggest a precise mode of DNA binding. A peculiarity of Ol-
Insm1b is the presence of a serine-rich sequence (SSSSSSSLA-
SSSSSSSSSSSS) upstream of zinc-finger 4; such a stretch of
amino acids is not present in either Ol-Insm1a, zebrafish or
mammalian Insm1 proteins.
The nomenclature of this molecule family is not fully stan-
dardised; indeed, in a recent paper (Lukowski et al., 2006) its
zebrafish members (Dr-Insm1a and Dr-Inms1b) are considered
to belong to the EIN (rather than the SNAG) protein family,
based on the sequence similarity of the zinc-fingers with those
of the EGF-46 (from Caenorhabditis) and Nerfin-1 (from
Drosophila) proteins. We decided to stick with the SNAG no-
menclature (Grimes et al., 1996), mostly because of the results
of our functional analyses.
Finally, we chose to match the names (1a and 1b) of the two
medaka paralogues with those of their zebrafish counterparts
based on: (i) sequence data, notably the above-mentioned subs-
titution in the SNAG domain, and (ii) expression data; indeed,
we have found that Ol-insm1b is not expressed until the end
of gastrulation. This is in contrast with zebrafish Dr-insm1a,
whose transcripts appear to be maternally contributed, whilst
those of Dr-insm1b are not (Lukowski et al., 2006).
Expression domains and time course
We have performed a detailed analysis of Ol-insm1b ex-
pression by WMISH in embryos and on histological sections of
adult brains. From this point of view also, Ol-insm1b is a typical
member of the Insm1 gene family: besides a strong and con-
served expression in the developing pancreas, its transcripts are
especially prominent in the CNS during the neurogenetic period
(Candal et al., 2005a).Ol-insm1b expression is especially strong
in the OT arrest zone as soon as this later becomes detectable
(Nguyên et al., 2001a), and in the developing hindbrain, where it
exhibits a transient banded pattern previously found in other
negative cell cycle regulators such as Ol-KIP and Ol-Gadd45γ
(Nguyên et al., 2001b; Candal et al., 2004, 2005a). Ol-insm1b
expression peaks at late somitogenesis stages and then decreases
as differentiation proceeds; it is turned off in most terminally
differentiated cells. Ol-insm1b continues to be strongly ex-
pressed in the medaka adult CNS, in a pattern similar to that
observed in embryos, albeit with some differences: notably, Ol-
insm1b mRNA is strongly and asymmetrically expressed in the
left habenula of the adult brain, whereas its expression is
symmetrical in the development of this diencephalic structure.
Structural asymmetries (notably in size) in the habenula are
widespread amongst vertebrates (Concha and Wilson, 2001).
While in medaka embryos the anlagen of the right and left
habenulas are similar in size, in adult brains, the left habenula is
clearly smaller than the right one (see Fig. 3), as it is in other
teleosts (Salmo trutta fario; Candal, 2002). This late appearance
of a size asymmetry is concomitant with the late asymmetry in
Ol-insm1b expression. Given its role in cell proliferation control
(see below), it is tempting to propose that Ol-insm1b precocious
expression in the smaller (left) habenula is linked with an earlier
arrest of cell cycle leading to its final smaller size, an intriguing
hypothesis which remains to be tested.
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of zebrafish Dr-insm1a and Dr-insm1b (Lukowski et al., 2006),
both spatially (expression domains, prominence in the pancreas
and CNS) and temporally (overall time course, peak at neuro-
genesis and later decrease).
These features are found beyond the teleostean lineage: in
mouse, Insm1 transcripts are detected from embryonic day 10.5
until 2 weeks post-partum, notably in the brain (Xie et al., 2002;
Breslin et al., 2003). Mammalian Insm1 is also expressed in
foetal pancreas, foetal brain and tumors of neuroendocrine ori-
gin (for example mouse pituitary tumor, rat medullary thyroid
carcinoma and human small cell lung carcinoma), but not in
most non-neuroendocrine tumors or normal adult tissues (inclu-
ding pancreas and brain; Goto et al., 1992; Lan et al., 1993,
1994).
These expression studies thus clearly point to a likely role for
the insm1 genes in CNS neurogenesis. In contrast with the
mammalian situation, we also detected a strong expression of
Ol-insm1b in the adult brain. It is quite possible that, since
neurogenesis is continuous in teleosts (Wullimann and Puelles,
1999; Zupanc, 1999; Wullimann and Knipp, 2000; Ekström et
al., 2001; Nguyên et al., 2001a; Candal et al., 2005c) this
expression simply reflects a different mode of brain growth
between teleosts and mammals.
Functional analysis
In vitro studies showed that Insm1 is a transcriptional
repressor (as are most if not all members of the SNAG family)
and that it regulates the NeuroD1 gene, an important factor in
pancreatic and neural development (Breslin et al., 2002, 2003);
it is also a target of Neurogenin3 and is required for normal
differentiation of pancreatic endocrine cells in vitro (Mellitzer
et al., 2006). However, to our knowledge, the role of Insm1
proteins in vivo has never been analysed.
Our first choice was to over-express Ol-insm1b in a cellular
context as close as possible as its physiological one, i.e., in
neural progenitors. To this aim, we generated transgenic F0
embryos where the expression of a VENUS-Ol-insm1b fusion
transgene was driven specifically in CNS proliferating cells by
the α1-tubulin promoter (Gloster et al., 1994, 1999). The clear
correlation between the fluorescence intensity in these embryos
and the reduction in size of their nervous system further points
to a role ofOl-insm1b in negative cell cycle control. However, it
was difficult to analyse these effects at a cellular level in these
mosaic embryos. We could not produce a stable transgenic line
with the α1-tubulin-VENUS-Ol-insm1b construct, the ubiquity (as
far as the CNS is concerned) and strength of the promoter (as
seen in our mosaic F0 embryos) affecting the viability of such
transgenic animals. We thus turned to experiments involving
over-expression in pre-MBT embryos, by mRNA injection at
the one-cell stage, a technique commonly used in fish and am-
phibian models. Admittedly, these experiments are less “physio-
logical” because Ol-insm1b expression starts at neurula stages.
They still represent ectopic expressions in an in vivo context
and allowed us to undertake a dissection of Ol-Insm1b func-
tional domains. A strong generalised ectopic expression (inject-ion at the one-cell stage) slows down early development in a
dose-dependent manner. This effect is strictly cell-autonomous,
as demonstrated by clonal experiments (injection of Ol-insm1b
mRNA in a single cell at the 32-cell stage). Flow cytometry
showed that Ol-insm1b causes a general shift away from pro-
liferation. Importantly, we never observed any evidence of
apoptosis in these experiments.
These results suggest that Ol-insm1b negatively regulates
cell proliferation in early embryos. It is of special importance to
emphasise that, whilst zinc-finger-containing proteins are best
known as transcriptional regulators, these strong effects of Ol-
insm1b on cell cycle were observed despite Insm1 proteins were
localised only in the cytoplasm. We were therefore confronted
to the seemingly paradoxical result of a likely transcriptional
repressor having a strong anti-proliferative effect in a largely
transcription-free context. This prompted us to check which
domains of Ol-Insm1b were responsible for its action.
The SNAG domain of various Snag and Gfi1 proteins is
essential for their repressor activity (Grimes et al., 1996; Naka-
yama et al., 1998; Okubo et al., 2001; Tateno et al., 2001;
Peinado et al., 2004; Fiolka et al., 2006). However, Snail and
Gfi1 proteins depend on the presence of the SNAG and the
zinc-finger domains for maximum repressor effect (Nakayama
et al., 1998; Tateno et al., 2001; McGee et al., 2003). We deleted
these domains of Ol-Insm1b to assess their functions in vivo.
The effects of constructs devoid of the SNAG domain are
identical, on pre-MBT embryos, to those of the full sequence.
Therefore, Ol-Insm1b negative effect on cell cycle progression
is not mediated by the SNAG domain.
Conversely, embryos injected with a construct lacking the
five zinc-fingers develop normally both before and after MBT,
suggesting that the zinc-finger motifs (or some of them) are
necessary for the autonomous, transcription-independent cell
cycle arrest in pre-MBT embryos.
It has been shown that zinc-finger 2 of the human IA-1/
Insm1 protein is critical for its activity (Breslin et al., 2003); we
thus checked the effects ofOl-insm1bΔzf1–2: embryos injected
with this construct develop normally before (but not after)
MBT, indicating that that zinc-finger 2 is necessary for cell
cycle arrest before MBT.
Furthermore, this strong anti-proliferative effect appears to
be specific of the Ol-Insm1b protein. Indeed, it is not mimicked
by injecting Ol-Mlt1 mRNA in the same conditions: this gene,
which is molecularly the “closest relative” of Ol-insm1 within
the SNAG family, does not induce any developmental delay.
These results show that Ol-Insm1b acts in pre-MBTembryos
via its zinc-finger motifs in a transcription-independent way.
This is also in good agreement with the cytoplasmic localisation
of the fusion protein observed in injections performed in one-
cell at the two-cell stages. A possible clue to this apparently
paradoxical phenomenon lies in the fact that C2H2-type zinc-
fingers are amongst the very few (the only others are the U1-like
type) to specifically bind both DNA and RNA, whilst 44 add-
itional families of zinc-finger proteins have been implicated in
either DNA–protein, protein–protein or protein–lipid binding
(Ravasi et al., 2003). For example, TFIIIA (the archetype of the
C2H2-containing proteins; Miller et al., 1985) is a dual RNA/
15E. Candal et al. / Developmental Biology 309 (2007) 1–17DNA-binding protein where individual C2H2 fingers make
different contacts with one or another nucleic acid, i.e., fingers
1–3 bind strongly to DNA, and central fingers 4–6 bind to RNA
(Searles et al., 2000; Brown, 2005). Although further studies are
clearly needed to elucidate the underlying mechanism(s), a
working hypothesis might therefore be that Ol-Insm1b nega-
tively regulates cell proliferation through a protein–RNA inter-
action rather than, or in addition to, a DNA-binding-based
mechanism.
When observed after gastrulation, embryos injected with the
full-length Ol-insm1b mRNA showed a dramatically reduced
size. While this may be due to the early (pre-MBT) decrease in
cell numbers, it also suggested late, or maintained, effects since
embryos have normally amazing capacities of recovery. This
hypothesis was strengthened by the injections of Ol-insm1b
Δzf1–2 constructs: in this case, embryos developed normally
before MBT, but exhibited a reduction in size and/or morpho-
logical defects after MBT. In this case, their reduced size could
therefore not be due to early cell cycles arrest. This can be taken
as an additional indication for an anti-proliferative role of Ol-
insm1b, a hypothesis that indeed appears compatible with all
experiments reported here.
An unexpected restriction of diffusion in early development
In medaka, as in zebrafish (Kimmel and Law, 1985), the early
cleavages (1-cell to 16-cell stage) are partial, andmolecules such
as mRNA or morpholinos spread uniformly amongst all daugh-
ter cells when injected in one blastomere of the 2- to 16-cell stage
embryos (Candal et al., 2004 and present results). Surprisingly,
when we injected a pRN3-VENUS-Ol-insm1b fusion construct in
one out of two, or one out of four blastomeres, we subsequently
observed fluorescence in the cytoplasm of only one half or one
fourth of the daughter cells, respectively; these cells were also
larger and less numerous, as expected given our previous
observations. The same restriction was observed, by ISH, for the
VENUS-Ol-insm1b mRNA, suggesting that the mRNAs, rather
than the proteins, are diffusion-restricted. We then checked the
effects of deleted constructs: whereas VENUS-Ol-insm1bΔzf1–2
(lacking the first and second zinc-fingers) behaves identically to
the full construct, VENUS-Ol-insm1bΔNH2 (lacking the NH2
terminal, including the SNAG domain) leads to a uniform
diffusion, both at the mRNA and protein levels. This suggests
that the signal(s) for restricting the diffusion in early blastomeres
are located at the 5′ end of the Insm1 mRNA molecule. Sub-
cellular localisation of mRNAs is a well-documented phenom-
enon, and it has been shown to be largely dependent on signals
located in the 3′ UTR of these molecules (Kloc et al., 2002; Van
de Bor and Davis, 2004); however, here the uneven mRNA
distribution is observed between different cells rather than
between different compartments of the same cell. More expe-
riments are needed to elucidate this phenomenon, which, to our
best knowledge, has not been reported before.
Our results thus indicate that Ol-insm1b is likely to play a
role in vertebrate development as a novel anti-proliferative
molecule: it functions as a negative regulator of the cell cycle,
without triggering the apoptotic pathway. At least part of thiseffect is mediated by Ol-Insm1b zinc-finger domains, but not
via a transcriptional mechanism. These results, added to the
already documented correlation between the deregulation of
Insm1 and neuroendocrine tumour progression in vertebrates,
open new perspectives in the field of cancer studies.
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